Shamburg News · 8-K filed Nov 16, 2026, 7:02 AM EST

Lexeo Therapeutics Reports Positive Interim LX2020 Data and Q3 2026 Results

LXEO · Lexeo Therapeutics, Inc.

  • Earnings
  • Reg FD disclosure
  • Other event
  • Leadership change
  • Materiality: high

Lexeo Therapeutics announced positive interim Phase I/II data for LX2020 in PKP2-associated arrhythmogenic cardiomyopathy, including an 80% mean reduction in NSVT in high-dose cohorts at latest assessment, and reported third quarter 2026 results. The company reported a net loss of $38.3 million, or $0.43 per share, for the three months ended September 30, 2026, and cash, cash equivalents and investments of $219.1 million. The filing also disclosed the appointment of Toby Schilke as an independent director.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, 8.01, 9.01, accession 0001193125-26-462015.

Written from the filing by Shamburg Markets. Figures are as reported by the company.